103372-25-4

Upstream product

• 35899-43-5 Boc-His(Tos)-OH 
• 103372-24-3 [(S)-1-((S)-1-Hydroxy-2-{(1S,2S)-2-methyl-1-[(pyridin-2-ylmethyl)-carbamoyl]-butylcarbamoyl}-ethyl)-3-methyl-butyl]-carbamic acid tert-butyl ester 
• 67010-43-9 (3S,4S)-ethyl 4-(tert-butoxycarbonylamino)-3-hydroxy-6-methylheptanoate 
• 103322-68-5 N-α-(tert-butyloxycarbonyl)-L-isoleucyl>-2-pyridylmethylamine 
• 97920-16-6 N-L-isoleucyl-2-pyridylmethylamine 
• 13139-16-7 N-(tert-butyloxycarbonyl)-L-isoleucine 
• 3731-51-9 2-(Aminomethyl)pyridine 

Downstream Products

• 112374-72-8 C₅₂H₇₂N₈O₁₀S 
• 97920-11-1 {(S)-1-[(S)-1-[(S)-1-((S)-1-Hydroxy-2-{(1S,2S)-2-methyl-1-[(pyridin-2-ylmethyl)-carbamoyl]-butylcarbamoyl}-ethyl)-3-methyl-butylcarbamoyl]-2-(1H-imidazol-4-yl)-ethylcarbamoyl]-2-phenyl-ethyl}-carbamic acid tert-butyl ester 
• 112374-79-5 C₆₅H₈₅N₁₁O₁₃S₂ 
• 103352-64-3 (S)-2-{(S)-1-[(S)-1-[(S)-1-((S)-1-Hydroxy-2-{(1S,2S)-2-methyl-1-[(pyridin-2-ylmethyl)-carbamoyl]-butylcarbamoyl}-ethyl)-3-methyl-butylcarbamoyl]-2-(1H-imidazol-4-yl)-ethylcarbamoyl]-2-phenyl-ethoxymethyl}-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 112398-40-0 C₄₅H₆₅N₉O₈ 
• 103352-65-4 C₅₁H₇₃N₁₁O₉ 
• 97920-13-3 ((S)-1-{(S)-2-(1H-Imidazol-4-yl)-1-[(S)-3-methyl-1-(2-{(1S,2S)-2-methyl-1-[(pyridin-2-ylmethyl)-carbamoyl]-butylcarbamoyl}-acetyl)-butylcarbamoyl]-ethylcarbamoyl}-2-phenyl-ethyl)-carbamic acid tert-butyl ester 
• 112374-82-0 ((S)-1-{(S)-1-[(S)-1-((S)-1-Hydroxy-2-{(1S,2S)-2-methyl-1-[(pyridin-2-ylmethyl)-carbamoyl]-butylcarbamoyl}-ethyl)-3-methyl-butylcarbamoyl]-2-[1-(toluene-4-sulfonyl)-1H-imidazol-4-yl]-ethylcarbamoyl}-2-phenyl-ethyl)-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Renin inhibitors containing ψ[CH2O]pseudopeptide inserts

Renin inhibitors 2-4 with the D-Lys renin inhibitory peptide (RIP) sequence, but containing Leuψ[CH2O]Ala (2), Leuψ[CH2O]Val (3), and Leuψ[CH2O]Leu (4) at the P1-P1' site, were of a comparable potency

Design and Synthesis of a Potent and Specific Renin Inhibitor with a Prolonged Duration of Action in Vivo

A structure-activity analysis of peptides containing backbone Cα-methyl and Nα-methyl modifications led to the discovery of potent renin inhibitors with high metabolic stability.In vitro, Boc-Pro-Phe-Nα-MeHis-Leuψ